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Abstract
Introduction: Combination antituberculosis drug therapy remains the mainstay of treating tuberculosis.
Unfortunately, antituberculosis drugs produce side effects including (toxic) impaired visual function, which may be
irreversible. We report a case of antituberculosis-drug-induced impaired visual function that was reversed following
early detection and attention.
Case presentation: A 37-year-old Yoruba woman, weighing 48 kg, presented to our facility with impaired visual
functions and mild sensory polyneuropathy in about the fourth month of antituberculosis treatment. Her therapy
comprised ethambutol 825 mg, isoniazid 225 mg, rifampicin 450 mg, and pyrazinamide 1200 mg. Her visual acuity
was 6/60 in her right eye and 1/60 in her left eye. She had sluggish pupils, red-green dyschromatopsia, hyperemic
optic discs and central visual field defects. Her intraocular pressure was 14 mmHg. Her liver and kidney functions
were essentially normal. Screening for human immunodeficiency virus was not reactive. Her impaired visual
function improved following prompt diagnosis and attention, including the discontinuation of medication.
Conclusions: The ethambutol and isoniazid in antituberculosis medication are notorious for causing impaired
visual function. The diagnosis of ocular toxicity from antituberculosis drugs should never be delayed, and should
be possible with the patient’s history and simple but basic eye examinations and tests. Tight weight-based
antituberculosis therapy, routine peri-therapy visual function monitoring towards early detection of impaired
function, and prompt attention will reduce avoidable ocular morbidity.
Introduction
Tuberculosis is a multisystemic and wide-ranging com-
municable disease across the globe, specifically in
resource limited economies. It is caused by a type of
acid-fast and alcohol-fast mycobacteria. The bacilli are
difficult to treat and there may be resistance, which is
common in immunosuppressed states, especially human
immunodeficiency virus (HIV) and/or acquired immu-
nodeficiency syndrome (AIDS). However, the ‘combina-
tion drug therapy’ employed in the treatment of
tuberculosis has been hailed as a medical breakthrough.
Various combination drug regimens are employed in
the treatment of tuberculosis. The common combina-
tion drug therapy is one comprising the ‘first-line’
antituberculosis drugs including ethambutol, isoniazid,
rifampicin and pyrazinamide [1].
Unfortunately, these drugs, despite being effective in
treating tuberculosis, produce a number of side effects,
including impaired visual function [1]. For example,
ethambutol is notorious for causing optic neuropathy
and chiasmopathy [2,3]. Furthermore, and disturbingly,
ethambutol is toxic to retinal ganglion cells via an
excitotoxic pathway [4]. Additionally, Isoniazid has
been implicated in optic neuropathy as well as periph-
eral neuropathy and hepatotoxicity [1,5]. Rifampicin is
notorious for micosomal enzyme induction and hepa-
totoxicity, while pyrazinamide has been associated with
hepatotoxicity, gastrointestinal upset and hyperurice-
mia [1].
The adverse effects of combination antituberculosis
medication may be related to drug dose and duration of
use [1] or may be idiosyncrasies.
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to adverse drug effects by way of impaired drug
metabolism.
This report highlights the sight restoration, following
early detection and attention, in a 37-year-old woman
who developed impaired visual function after four
months on high-dosage combination antituberculosis
therapy. Recommendations on routine vision screening
and monitoring of patients on antituberculosis drugs
towards early detection and attention are discussed.
Case report
Our patient was a 37-year-old, 48 kg Yoruba woman,
who developed impaired visual function while on treat-
ment for pulmonary tuberculosis. She was diagnosed as
having pulmonary tuberculosis based on a history of
chronic cough, weight loss, positive acid- and alcohol-
fast bacilli sputum examinations and reticulonodular
chest features of pulmonary tuberculosis evident on
radiology (Figure 1).
She successfully completed a two-month intensive
treatment course on a daily four-drug combination com-
prising ethambutol 825 mg, isoniazid 225 mg, rifampicin
450 mg, and pyrazinamide 1200 mg. Our patient’s
weight improved to 52 kg. This two-month course was
followed by a continuous phase of treatment. This com-
prised a daily two-drug combination including ethambu-
tol 825 mg and isoniazid 450 mg. The two-drug
combination was, however, substituted with only rifam-
picin about 11 weeks into the continuous phase when
our patient reported blurred vision at the chest clinic
where she was being managed. There was total withdra-
wal of the antituberculosis drug about two weeks later
on account of persistent impaired visual function. By
then, our patient had been receiving antituberculosis
t h e r a p yf o rap e r i o do ff i v em o n t h s ,i n c l u d i n gt h et w o -
month intensive and three-month continuous phases.
She presented to our eye clinic about nine days after
her antituberculosis drugs had been discontinued on
account of her progressive painless diminishing vision of
approximately one month’s duration. Our patient also
complained of a tingling sensation in her lower limbs.
There was no record of a visual assessment before and
during her therapy, however, our patient stated she had
had normal vision previously. She had no family history
of significant blinding ocular conditions and did not
wear glasses. Furthermore, our patient had no history
suggestive of diabetes mellitus, hypertension, sickle cell
disease or HIV and/or AIDS.
A physical examination on presentation showed a
wasted and concerned patient, however her vital signs
were normal. Her visual acuity (VA) was 6/60 in her
right eye and 1/60 in her left eye. She had red-green
dyschromatopsia using Ishihara color plates and her
pupils were sluggish in their response to light. Her optic
discs were hyperemic. Her intraocular pressure was 14
mmHg in both eyes. She had central visual field (CVF)
defects (Figure 2a, b). Biochemical tests to assess kidney
and liver function were essentially normal except for
elevated alkaline phosphatase (Table 1). A screening for
HIV was not reactive.
Except for multivitamins (Dolo-Neurobion
® taken
orally daily) taken by our patient for three weeks, our
patient was not on any other medication. She was coun-
seled and reassured of a high chance of visual recovery
over time. Our patient was monitored in our eye clinic
at two-weekly intervals. At each visit, aside from our
patient’s briefings on visual function, her VA, color
vision, pupillary activities and funduscopy were checked
and documented. Her VA initially got worse, declining
to 1/60 in both eyes two weeks after initial presentation,
but later improved steadily following the discontinuation
of the antituberculosis therapy. Our patient was last
reviewed by our eye clinic nine months after her initial
presentation, and her VA was recorded as unaided VA
right eye 6/24-1, left eye 6/12+2 and aided (using cor-
rection with lenses; right eye -2.75DS, left eye -1.00DS)
VA right eye 6/9-2, left eye 6/6-3. A repeat CVF test
(Figure 3a, b) performed eight months after her initial
CVF showed that the CVF defects had disappeared.
Discussion
Antituberculosis drugs, as with many other drugs, pro-
duce unwanted side effects, especially when used at high
dosages and usually for periods of more than two
Figure 1 Chest radiograph of our patient on presentation to
our clinic.
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including the eyes, kidneys, liver, and blood tissues.
Our patient had normal hepatic and renal function on
antituberculosis medication, as revealed by her normal
biochemical indices. This suggests that the drug toxicity
was not related to impaired liver or renal function. The
screening for HIV in our patient, though negative, was
desirable, as tuberculosis can coexist with HIV/AIDS
[6]. Our patient was in the sexually active catchment
age where HIV/AIDS is common.
Of the four drugs in the combination antituberculosis
therapy, both ethambutol and isoniazid are capable of
causing the impaired visual function seen in our patient.
Ethambutol, especially, is notorious for causing optic
neuropathy, chiasmopathy, and retinal toxicity. The dose
of ethambutol as used in our patient was above 15 mg/
kg, a level at which ocular toxicity is common [5]. How-
ever, vision loss even with much lower doses is not
impossible in idiosyncratic situations. Furthermore, our
patient had used both ethambutol and isoniazid for
more than four months, a duration sufficient to produce
ocular toxicity [5].
The neurovitamins (Dolo-Neurobion including vita-
min B6) were expected to augment visual recovery.
However, restoration of impaired visual function may
have been achieved without neurovitamin supplements
once the suspected toxic agent was discontinued, and of
course before damage became irreversible. Our patient
had a sudden onset of diminishing visual acuity that gra-
dually improved over a period of months after disconti-
nuation of medication and was not necessarily based on
any specific medication, including the use of neurovita-
mins. Furthermore, the background fundal findings of
hyperemic optic discs, red-green dyschromatopsia, and
sluggish pupillary activity in our patient, as well as CVF
defects, all reinforced our suspicion of toxic neuropathy,
specifically caused by ethambutol and worsened by
isoniazid.
The relevant history of impaired visual functioning
while on antituberculosis drugs including ethambutol
and isoniazid, and basic eye examinations and tests were
sufficient for accurate diagnosis and hence suitable
intervention to save the sight in our patient. This
approach should be sufficient in saving the sight of
patients on antituberculosis medication elsewhere as
well. This benefit is further underscored as it can be
achieved without sophisticated medical tests, which are
not readily available in many societies. However, tests
including multifocal electroretinogram (mfERG) and
visual evoked potential (VEP) could suggest associated
A
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Figure 2 CVF (a) left eye and (b) right eye, during impaired
visual function.
Table 1 Blood biochemical parameters in our patient
Biochemical parameter Normal reference value Patient value
Bilirubin total, μmol/L Up to 20 1.8
Bilirubin conjugated, μmol/L 5 0.5
Protein total, g/L 58 to 80 70.0
Albumin, g/L 35 to 50 42.0
Creatinine, μmol/L 50 to 110 90.0
Bicarbonate, μmol/L 20 to 30 26.0
Chloride, mmol/L 95 to 110 104.0
Potassium, mmol/L 3 to 5 3.8
Sodium, mmol/L 120 to 140 129.0
Urea, mmol/L 1.7 to 9.1 1.9
Alkaline phosphatase, IU 21 to 107 138.0
Alanine transferase, IU 4 to 18 7.0
Aspartate transferase, IU Up to 22 4.0
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from mfERGs have been found to be abnormal in
ethambutol-induced macular toxicity, and should there-
fore be useful in diagnosis and serial assessment of
ethambutol-related ocular toxicity [7]. Furthermore,
where available and affordable, tests such as magnetic
resonance imaging (MRI) and optical coherence tomo-
graphy (OCT) [8] could be employed to investigate
ethambutol ocular toxicity. MRI scans of the optic
nerves and chiasm, with normal findings in toxic and/or
nutritional optic neuropathy, could be useful to differ-
entiate between bilateral cecocentral scotomas and
compressive or infiltrative lesions of the optic chiasm.
OCT, being an objective test, could be used to quantify
the loss of retinal nerve fibers from the optic nerves as a
sign of early toxicity from ethambutol [8].
It was found that our patient, as in many others in
resource-limited communities, had received no peri-
therapy visual assessment. However, early report and
detection, prompt referral, and prompt attention con-
tributed to restoration of visual function in our patient.
A p a r tf r o mt h i s ,o u rp a t i e n tb e n e f i t e df r o mad i s c o n t i -
nuation of drugs, which of course remains the mainstay
of treating ethambutol-associated and isoniazid-asso-
ciated ocular toxicity [5].
Irreversible visual impairment as a consequence of
antituberculosis medication may not be common, but it
does complicate the management of tuberculosis and
compromises patient quality of life. Increasing patient,
health worker and facility preparedness for identifying
and managing symptoms or signs of possible visual
complications of ethambutol and isoniazid use may
assist in preventing cases of irreversible visual impair-
ment from antituberculosis medication.
Patients on antituberculosis medication (and their par-
ents or guardians) may also benefit from health educa-
tion on possible visual complications of ethambutol and
isoniazid. Where possible, patients could be taught how
to assess VA and how to perform color vision tests for
self-monitoring of visual function. These charts could be
made available for patients to use at home. Patients
could then report to their clinic (in person or by tele-
phone) in case of visual complaints or detected visual
defects.
Furthermore, the attending health staff could be trained
on the possible ocular side effects of ethambutol and iso-
niazid, including visual impairment and color vision
defects. They should specifically ask patients about these
at each clinic visit (screening). They should also carry out
tests on patients, interpret VA and color vision test results
for possible changes and advise discontinuation of drugs,
promptly referring patients to eye care specialists.
Finally, involved health facilities should routinely
assess patients for visual function while on antitubercu-
l o s i sd r u gt h e r a p y .T h i sc o u ld be achieved by referring
patients for visual function assessment before, during
and after drug therapy. Alternatively, trained health staff
in such facilities could be involved in peri-therapy visual
assessment, as already mentioned. The required mini-
mum for peri-therapy visual function assessment for
patients on ethambutol and isoniazid drugs should be
VA and color vision tests. The health facility could
make visual acuity and color vision charts available.
Following the advocacy visit to the chest clinic, where
our patient was being managed, the coordinator in
A
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Figure 3 CVF (a) left eye and (b) right eye, months after
discontinuation of drugs.
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our above recommendations. The prompt referral of
patients with ocular complaints and/or detected ocular
abnormalities to eye care specialists can prevent ocular
morbidity and/or mortality among patients on antituber-
culosis drugs.
Conclusions
Ethambutol and isoniazid used in antituberculosis treat-
ment are notorious for causing impaired visual function.
A diagnosis of ocular toxicity from antituberculosis
d r u g ss h o u l dn e v e rb ed e l a y e d ,a n ds h o u l db ep o s s i b l e
with patient history and simple but basic eye examina-
tions and tests. Tight weight-based antituberculosis
therapy, routine peri-therapy visual function monitoring
towards early detection of impaired functions, and
prompt attention will reduce avoidable ocular morbidity
among patients on antituberculosis drugs.
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